Back to News & Events

Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension

Share this

About this Poster:

Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, increased nitric oxide (NO)-mediated signaling and reduced fasting plasma glucose and proteinuria in an animal model of diabetic nephropathy. In healthy subjects, repeated oral doses of praliciguat (15-40 mg) were well tolerated and lowered blood pressure (BP). We evaluated 2 dosing regimens of praliciguat in a phase 2a trial in patients with type 2 diabetes mellitus (T2DM) and hypertension (HTN).

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.